Ischemic Placental Disease and Maternal Hospitalization for Neurological and Psychiatric Disorders: A Comprehensive Review

Highlights

• Ischemic placental disease (IPD)—including preeclampsia, placental abruption, and fetal growth restriction—is linked to increased postpartum hospitalizations for neurological and psychiatric disorders in reproductive-aged women.
• The degree of manifestation of IPD correlates with stepwise increased hazards for brain disorder hospitalization, indicating a dose-response relationship.
• Impaired cerebral autoregulation, altered maternal hemodynamics, and elevated cerebral biomarkers underline mechanistic pathways linking placental ischemia and brain vulnerability.
• Postpartum neuropsychiatric morbidity associated with IPD highlights the need for integrated maternal care, including mental health surveillance and vascular risk assessment beyond delivery.

Background

Ischemic placental disease (IPD) encompasses a spectrum of obstetric syndromes defined by impaired uteroplacental perfusion, namely preeclampsia (PE), placental abruption, and fetal growth restriction (FGR). These conditions are unified by ischemic, endothelial, and microvascular dysfunction of placental vasculature, leading not only to adverse perinatal outcomes but also signifying systemic maternal vascular pathology.

Emerging research reveals IPD as a sentinel marker for maternal brain vulnerability, potentially resulting in structural brain abnormalities, disturbed neuronal connectivity, and inadequate neurogenesis. Such pathophysiological changes may predispose women to neurological events (stroke, transient ischemic attacks, migraines, epilepsy) and psychiatric conditions (major and postpartum depression, anxiety disorders, PTSD, bipolar disorder, psychosis) during and after the peripartum period.

Despite clinical attention to IPD’s immediate obstetric risks, its implications for maternal neurological and psychiatric morbidity in the postpartum period remain under-investigated. This review aims to integrate contemporaneous epidemiological, mechanistic, and clinical data to elucidate the nexus between IPD and postpartum brain disorders.

Key Content

Population-Based Evidence Linking IPD to Postpartum Brain Disorders

The landmark population-based retrospective cohort study by Ananth et al. (2026) analyzed over 17 million U.S. hospital deliveries (2010-2020) using the Nationwide Readmissions Database. IPD diagnosis was recorded in 10.7% of deliveries. The incidence of hospitalization for neurological and psychiatric disorders within the delivery year was significantly higher in women with IPD (1219 per 10,000) compared to those without (730 per 10,000), with an adjusted hazard ratio (aHR) of 1.50 (95% CI 1.48-1.51).

Furthermore, a dose-response relationship was evident: women with one IPD condition had an aHR of 1.47, those with two had 1.66, and women with all three (preeclampsia, abruption, FGR) had an aHR of 1.85 for brain disorder hospitalization. These associations persisted after quantitative bias analysis for outcome misclassification and unmeasured confounding, underscoring the robustness of findings.

Neurological Morbidity: Mechanistic and Clinical Correlates

Preeclampsia is characterized by cerebral autoregulation impairment and increased blood pressure variability (BPV) postpartum, as demonstrated by studies monitoring mean arterial pressure and cerebral oxygen saturation (Slovut et al., 2025; https://pubmed.ncbi.nlm.nih.gov/40629211/). Higher BPV correlates with prolonged time outside personalized cerebral autoregulatory limits, increasing susceptibility to hypoperfusion or hyperperfusion injuries.

Static cerebral autoregulatory curves further reveal widened autoregulatory ranges in preeclamptic women postpartum, potentially increasing stroke risk (Richards et al., 2025; https://pubmed.ncbi.nlm.nih.gov/40845907/).

Additionally, elevated plasma levels of cerebral biomarkers neurofilament light, tau protein, and glial fibrillary acidic protein in women with preeclampsia—especially those with neurologic complications such as eclampsia and stroke—reflect neuroaxonal injury and offer potential diagnostic and prognostic utility (Matjaž et al., 2022; https://pubmed.ncbi.nlm.nih.gov/35257666/).

Epidemiological data from the Framingham Heart Study demonstrate that women with a history of preeclampsia have increased long-term risk of stroke later in life, with a relative risk of 3.79 after adjustment for vascular risk factors (Smith et al., 2021; https://pubmed.ncbi.nlm.nih.gov/33900402/).

Psychiatric Morbidity Associated With IPD

Postpartum depression (PPD) and anxiety disorders disproportionately affect women with hypertensive pregnancy disorders. Though direct longitudinal associations between IPD and PPD over extended periods are equivocal (Miller et al., 2026; https://pubmed.ncbi.nlm.nih.gov/42176084/), evidence supports that preexisting psychiatric history and recent stressors are strong predictors of postpartum mood symptoms.

Chronic migraine, frequently comorbid with preeclampsia, independently increases odds for PPD, highlighting the intersectionality of neurological and psychiatric morbidity in this population (Kumar et al., 2025; https://pubmed.ncbi.nlm.nih.gov/40171673/).

Mobile health platforms like PowerMom have demonstrated potential utility in postpartum mental health monitoring, showing that women receiving treatment for anxiety or depression during pregnancy report increased physical symptoms and worse postpartum mental health outcomes, suggesting the need for proactive mental health screening in the context of IPD (Chang et al., 2025; https://pubmed.ncbi.nlm.nih.gov/40402566/).

Maternal Hemodynamics and Placental Biomarkers: Predictive and Mechanistic Insights

Hemodynamic studies reveal that women with gestational diabetes and preeclampsia exhibit increased arterial stiffness, elevated pulse wave velocity, and altered cardiac output late in pregnancy, indicating early vascular disease that may contribute to both placental pathology and long-term cerebrovascular sequelae (Nordén et al., 2024; https://pubmed.ncbi.nlm.nih.gov/39363522/).

Non-invasive measures such as uterine artery pulsatility index and maternal vascular resistance correlate with placental function, aiding in the early identification of women at risk for hypertensive disorders and fetal growth restriction (Solli et al., 2022; https://pubmed.ncbi.nlm.nih.gov/33586584/).

By integrating maternal vascular status with biochemical markers (placental growth factor, soluble fms-like tyrosine kinase-1), prediction of preeclampsia onset and severity improves, with implications for timely clinical intervention and potentially reducing maternal neurological sequelae (Birkeland et al., 2024; https://pubmed.ncbi.nlm.nih.gov/37778678/).

Expert Commentary

The association between ischemic placental disease and maternal brain health is supported by robust epidemiologic data, mechanistic vascular and cerebral biomarker studies, and neuropsychiatric outcome assessments. The dose-response relationship affirms a pathophysiological continuum where microvascular endothelial dysfunction intrinsic to IPD extends beyond the placenta to involve cerebral vasculature, impair cerebral autoregulation, and predispose to neurological and psychiatric morbidities postpartum.

The postpartum period, traditionally viewed primarily concerning obstetric recovery, emerges as a critical window for brain health monitoring. Neurological complications may be under-recognized drivers of maternal morbidity and mortality. Psychiatric disorders concomitant with neurological vulnerability necessitate integrated biopsychosocial care models.

Limitations include potential residual confounding in retrospective analyses and incomplete mechanistic understanding of neuronal injury pathways. Notably, psychiatric morbidity’s multifactorial nature mandates consideration of preexisting vulnerability, psychosocial stressors, and peripartum events.

Clinical guidelines should incorporate maternal cerebral and mental health surveillance, particularly in women with IPD histories. Early identification of cerebrovascular irregularities via non-invasive monitoring and biomarker assays could inform individualized postpartum management.

Future research should target prospective longitudinal designs assessing the impact of IPD on maternal brain structure and function, explore intervention strategies to mitigate cerebral vascular injury, and validate predictive biomarkers.

Conclusion

Ischemic placental disease is a significant risk factor for postpartum neurological and psychiatric hospitalizations, reflecting systemic microvascular and endothelial pathology that affects maternal brain health. These findings advocate for a paradigm shift in postpartum care emphasizing vascular and mental health surveillance to improve lifelong outcomes for women complicated by IPD.

Addressing this convergence of obstetric and neuropsychiatric morbidity offers the prospect of reducing maternal morbidity and enhancing quality of life. Integrated multidisciplinary care strategies and targeted research efforts remain imperative.

References

• Ananth CV, et al. Ischemic Placental Disease and Hospitalization for Neurological and Psychiatric Disorders. Am J Obstet Gynecol. 2026 Jul 10; PMID: 42431247.
• Slovut DP, et al. Increased Blood Pressure Variability and Cerebral Autoregulation in Postpartum Preeclampsia. Neurocrit Care. 2025 Dec; PMID: 40629211.
• Richards EM, et al. Aggregated Postpartum Cerebral Autoregulatory Curves in Preeclampsia. Physiol Meas. 2025 Sep; PMID: 40845907.
• Matjaž K, et al. Cerebral Biomarkers in Neurologic Complications of Preeclampsia. Am J Obstet Gynecol. 2022 Aug; PMID: 35257666.
• Smith AJ, et al. Association of Preeclampsia With Incident Stroke in Later Life. JAMA Netw Open. 2021 Apr; PMID: 33900402.
• Miller CA, et al. Relationship of Hypertensive Disorders of Pregnancy with Postpartum Mood and Anxiety. Arch Womens Ment Health. 2026 May; PMID: 42176084.
• Kumar S, et al. Postpartum Depression in Patients with Chronic Migraine. J Womens Health. 2025 Aug; PMID: 40171673.
• Chang T, et al. Using the PowerMom Digital Health Platform to Support Prenatal Mental Health. JMIR Ment Health. 2025 May; PMID: 40402566.
• Nordén M, et al. Maternal Vascular Indices in Gestational and Pre-existing Diabetes Mellitus. Ultrasound Obstet Gynecol. 2024 Nov; PMID: 39363522.
• Solli C, et al. Maternal Hemodynamic Assessment and Prediction of Preeclampsia. J Matern Fetal Neonatal Med. 2022 Dec; PMID: 33586584.
• Birkeland KI, et al. Maternal Vascular Indices at 36 Weeks’ Gestation in the Prediction of Preeclampsia. Am J Obstet Gynecol. 2024 Apr; PMID: 37778678.